New CANCER RISK Stratification Test for Barrett's Esophagus
Cernostics, Inc. is the developer and marketer of the FIRST clinical assay for Barrett's Esophagus that PREDICTS THE RISK of Esophageal Cancer. The patented TissueCypher™ BE Assay utilizes a clinically-verified biomarker-based tissue systems approach that has 3x the cancer-predicting accuracy of expert GI pathology and 6x the accuracy of standard GI pathology.
Brands: Cernostics' new Tissue-Cypher™ Barrett's Esophagus Assay identifies high risk BE patients that are 9.4 times more likely to progress to HGD/EAC within 5 years of biopsy vs. low risk patients
DDW Tracks Basic Science, Microbiome in Gastrointestinal and Liver Diseases
Does your company only service US attendees? Yes